As of Nov 19, 2026, 2 of 2 active firms rate SPRY a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
SPRY EPS & revenue forecast
EPS · NEXT QUARTER
$-0.32
Range $-0.36 – $-0.27 · 2 analysts · -48% YoY
Next period, 2 analysts expect ARS Pharmaceuticals, Inc to earn $-0.32 a share (range $-0.36 – $-0.27), versus $-0.61 a year earlier. Full-year consensus is $-1.91, growing to $-0.82 the year after.
REVENUE · NEXT QUARTER
$25.2M
Range $24.5M – $26.5M · 2 analysts · +11% YoY
Revenue is expected to reach $25.2M (range $24.5M – $26.5M), +11.1% year-over-year. Full-year consensus is $120.4M, rising to $165.4M next year.
Top analysts covering ARS Pharmaceuticals, Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on SPRY.
#1
Josh Schimmer
Cantor Fitzgerald · Rank #132
Buy
$30.00+710.8% to target
Overall win rate
44%
+ Follow
#2
JW
Jason Wittes
Roth MKM · Rank #382
Buy
$40.00+981.1% to target
Overall win rate
40%
+ Follow
#3
Roanna Ruiz
SVB Leerink · Rank #513
Buy
$18.00+386.5% to target
Overall win rate
30%
+ Follow
#4
Ryan Deschner
Raymond James
Buy
No targeton SPRY
Coverage
—
+ Follow
#5
Carl Byrnes
Northland Capital Markets
Buy
$25.00+575.7% to target
Coverage
—
+ Follow
SPRY stock forecast FAQ
What is SPRY's average 12-month price target?+
The 2 active firms with a live target average $24.00 for ARS Pharmaceuticals, Inc over the next 12 months, ranging from a $30.00 high to a $18.00 low, as of Nov 19, 2026.
Is SPRY stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 2 active firms as of Nov 19, 2026, 2 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for SPRY?+
The Street-high target is $30.00 (Cantor Fitzgerald), and the Street-low is $18.00 (Leerink Partners). The average of all 2 active-firm targets is $24.00.
How many active Wall Street firms cover SPRY?+
2 active firms have a recognized rating on ARS Pharmaceuticals, Inc as of Nov 19, 2026, and 2 active firms carry a live 12-month price target.
Who is the most accurate analyst covering SPRY?+
Among analysts who currently cover SPRY, Josh Schimmer of Cantor Fitzgerald has the strongest overall Quantellect track record (Rank #132). Their current call is Buy with a $30.00 target.
What is ARS Pharmaceuticals, Inc's projected EPS for next quarter?+
The consensus estimate is $-0.32 per share (range $-0.36 – $-0.27) across 2 analysts. Full-year EPS is projected at $-1.91, rising to $-0.82 the following year.
How much revenue is ARS Pharmaceuticals, Inc expected to report next quarter?+
Consensus revenue is $25.2M (range $24.5M – $26.5M). Full-year revenue is projected at $120.4M, growing to $165.4M next year.
Have analysts been upgrading or downgrading SPRY lately?+
As of Nov 19, 2026, 2 of 2 active firms rate SPRY a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their SPRY calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.